A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
996actual
Sites
322
Countries
Argentina, Australia, Austria +29
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-06-22 | actual | When the study began enrolling |
| Primary completion | 2024-11-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2020-01-18 | actual | When this record first appeared on the registry |
| Results posted | 2025-12-15 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Crohn's Disease
Intervention
- Drug: Mirikizumab — also filed as LY3074828
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Achieving Endoscopic Response at Week 52 (Participants Originating From AMAM Study)
measured Week 52
Percentage of Participants Achieving Clinical Remission at Week 52 (Participants Originating From AMAM Study)
measured Week 52
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-09-10 · 2.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-09-10 · 1.6 MB · SAP_001.pdf
Publications
- PMID 41794217 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed